Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

MU Health Care said the new program is the only one of its kind in the region, and may help patients get care without going ...

March Biosciences, a startup spun out of Baylor College of Medicine's Center for Cell and Gene Therapy, landed a Series A ...

ImmPACT’s lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate that Lyell ...

Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at ...

In 1893, the American Journal of the Medical Sciences reported on 10 patients whose large and hitherto incurable cancers had ...

For heart failure specialists new to the cardio-oncology realm, the paper advises on patient care and what’s known thus far.

This study, being conducted in South Africa, is similar to ImmunityBio’s U.S.-based trial QUILT 3.092, a phase 1 open-label study of CD19 t-haNK as a single agent and in combination with the company’s ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...